search
for
 About Bioline  All Journals  Testimonials  Membership  News  Donations


Indian Journal of Cancer
Medknow Publications on behalf of Indian Cancer Society
ISSN: 0019-509X EISSN: 1998-4774
Vol. 45, Num. 2, 2008, pp. 72-72

Indian Journal of Cancer, Vol. 45, No. 2, April-June, 2008, pp. 72

Letter To Editor

Need for the appraisal of uncommon side effects of a commonly prescribed drug- Imatinib

Department of Medical Oncology, Yashoda Hospitals, Hyderabad,
Correspondence Address:Department of Medical Oncology, Yashoda Hospitals, Hyderabad,
sureshattili@yahoo.com

Code Number: cn08019

Dear Sir,

The concept of targeted therapy is emerging as an innovative, high potential new trend in cancer therapy. These drugs are not supposed to affect the normal cells and act selectively on cancer cells there by minimizing the systemic side-effects. However the results are not as expected. One of such novel drugs (first of its kind to be approved by FDA) is Imatinib, a Bcr-Abl tyrosine kinase inhibitor. It has been used in patients of chronic myeloid leukemia and Gastro Intestinal Stromal Tumor (GIST) and has been under evaluation for many more indications. It is usually well tolerated, with relatively minor toxicities like fluid retention and skin changes. However, with the time, oncologists are noticing newer side effects which were not reported in the initial phases of drug trials. The more recently reported ones are, Ototoxicity, [1] cardio toxicity [2] and optic neuritis. [3] It is probably due to the mitochondrial dysfunction as hypothesized by Grazette et al , in their in vitro studies. [4] This entity requires further attention as majority of the patients receiving therapy are relatively young, the therapy often leads to long disease-free survival and the toxicity [mitochondrial damage leading to cardio toxicity and neurotoxicity] results in considerable morbidity.

References

1.Attili VS, Bapsy PP, Anupama G, Lokanatha D. Irreversible sensorineural hearing loss due to Imatinib. Leuk Res 2008;32:991-2.  Back to cited text no. 1  [PUBMED]  [FULLTEXT]
2.Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, et al . Cardiotoxicity of the cancer therapeutic agent Imatinib mesylate. Nat Med 2006;12:908-16.   Back to cited text no. 2    
3.Govind Babu K, Attili VS, Bapsy PP Anupama G. Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia. Int Ophthalmol 2007;27:43-4.  Back to cited text no. 3    
4.Grazette LP, Kerkela R, Patten R. Imatinib mesylate (Gleevec) induces mitochondrial dysfunction and caspase activation in cardiac myocytes. J Card Fail 2005;11:S126.  Back to cited text no. 4    

Copyright 2008 - Indian Journal of Cancer

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2019, Site last up-dated on 02-May-2019.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Internet Data Center of Rede Nacional de Ensino e Pesquisa, RNP, Brazil